Amicus Therapeutics, Inc. (FOLD)

Check out top investors' recommendation for FOLD
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
15.33
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company’s development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company’s primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Ritu Baral Canaccord Genuity Buy   Sep 13, '17     18.00  Sep 13, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Aug 07, '17     16.00  Aug 07, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Jun 25, '17     12.00  Jun 25, '18  N/A 
Ritu Baral Canaccord Genuity Buy   May 15, '17     12.00  May 15, '18  N/A 
Edward Nash Cowen And Company Buy   Dec 08, '16     12.00  Dec 08, '17  N/A 
Ritu Baral Canaccord Genuity Buy   Feb 22, '16   7.16  13.00  Feb 22, '17  -16.06% 
Ritu Baral Canaccord Genuity Buy   Jan 13, '16   6.54  13.00  Jan 13, '17  -14.53% 
Ritu Baral Canaccord Genuity Buy   Oct 05, '15   6.85  13.00  Oct 05, '16  6.57% 
Joseph Schwartz Leerink Swann Llc Buy   Oct 05, '15   6.85  21.00  Oct 05, '16  6.57% 
Joseph Schwartz Leerink Swann Llc Buy   Mar 04, '15   8.41  13.00  Mar 04, '16  54.58% 
Kimberly Lee Janney Capital Markets Buy   Jul 01, '14   3.99    Jul 01, '15  254.64% 
Joseph Schwartz Leerink Swann Llc Buy   Jul 01, '14   3.99  6.00  Jul 01, '15  254.64% 
Enoch Kuo Unaffiliated Buy   Jul 02, '13   2.41  5.00  Jul 02, '14  65.56% 
Gregory Wade Wedbush Securities Inc. Sell   Dec 20, '12   3.06  1.50  Dec 20, '13  30.72% 
Joseph Schwartz Leerink Swann Llc Buy   Dec 19, '12   5.77  5.00  Dec 19, '13  -13.34% 
Ritu Baral Canaccord Genuity Buy   Dec 19, '12   5.77  6.00  Dec 19, '13  -65.86% 
Mayank Gandhi Capstone Investments Buy   Oct 31, '12   5.07  7.00  Oct 31, '13  -58.19% 
Ritu Baral Canaccord Genuity Buy   Jul 17, '12   6.02  11.00  Jul 17, '13  -61.96%